A trial to evaluate the effect of the sodium–glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)

on behalf of the DAPA-HF Committees and Investigators

Research output: Contribution to journal › Article › peer-review

208 Scopus citations

Fingerprint

Dive into the research topics of 'A trial to evaluate the effect of the sodium–glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)'. Together they form a unique fingerprint.

Medicine & Life Sciences